Overview
The University of Maryland Marlene and Stewart Greenebaum Cancer Center is located on the medical campus of the University of Maryland, Baltimore, and is part of both the University of Maryland Medical Center and the University of Maryland School of Medicine. All of the center's researchers and physicians are on the faculty of the medical school and other professional schools at the University of Maryland, Baltimore.
UMGCC has developed a reputation as an institution with expertise in laboratory and clinical research providing innovative approaches to cancer treatment. The center actively participates in new drug development and conducts pilot studies and Phase I, II and III clinical trials. Research performed at the UMGCC has received significant national and international recognition, particularly honoring the pioneering work of Angela Hartley Brodie for the development of aromatase inhibitors for the treatment of breast cancer.
In addition to basic and clinical cancer research, cancer center activities include teaching and a strong focus on aggressive treatment for cancer patients in the 40-bed inpatient unit, dedicated Bone Marrow/Stem Cell Transplantation unit, and 25,000-square-foot (2,300 m2) outpatient facility, which opened in 2005.
The center has multidisciplinary clinical programs for all major cancers (breast, brain, cutaneous, head and neck, gastrointestinal, genitourinary, gynecological, hematologic malignancies, and thoracic cancer). Oncology clinical activities interact closely with the Cancer and Leukemia Group B (CALGB) in the areas of leukemia, breast cancer, small cell lung cancer, and lymphoma. Faculty participate in all aspects of protocol development, design, and implementation, and many protocols are currently chaired or co-chaired by our faculty.
Read more about this topic: University Of Maryland Greenebaum Cancer Center